CA2944118C - Topical composition for use in the treatment of inflammatory bowel disease - Google Patents

Topical composition for use in the treatment of inflammatory bowel disease Download PDF

Info

Publication number
CA2944118C
CA2944118C CA2944118A CA2944118A CA2944118C CA 2944118 C CA2944118 C CA 2944118C CA 2944118 A CA2944118 A CA 2944118A CA 2944118 A CA2944118 A CA 2944118A CA 2944118 C CA2944118 C CA 2944118C
Authority
CA
Canada
Prior art keywords
lactobacillus
composition
composition according
bifidobacterium
hyaluronic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2944118A
Other languages
English (en)
French (fr)
Other versions
CA2944118A1 (en
Inventor
Andrea BIFFI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sofar SpA
Original Assignee
Sofar SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sofar SpA filed Critical Sofar SpA
Publication of CA2944118A1 publication Critical patent/CA2944118A1/en
Application granted granted Critical
Publication of CA2944118C publication Critical patent/CA2944118C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2944118A 2014-04-23 2015-04-22 Topical composition for use in the treatment of inflammatory bowel disease Active CA2944118C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI2014A000751 2014-04-23
ITMI20140751 2014-04-23
PCT/IB2015/052938 WO2015162570A1 (en) 2014-04-23 2015-04-22 Topical composition for use in the treatment of inflammatory bowel disease

Publications (2)

Publication Number Publication Date
CA2944118A1 CA2944118A1 (en) 2015-10-29
CA2944118C true CA2944118C (en) 2020-06-30

Family

ID=50981755

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2944118A Active CA2944118C (en) 2014-04-23 2015-04-22 Topical composition for use in the treatment of inflammatory bowel disease

Country Status (6)

Country Link
US (2) US11464814B2 (cg-RX-API-DMAC10.html)
EP (1) EP3134072A1 (cg-RX-API-DMAC10.html)
JP (1) JP2017513906A (cg-RX-API-DMAC10.html)
CA (1) CA2944118C (cg-RX-API-DMAC10.html)
MA (1) MA39710A (cg-RX-API-DMAC10.html)
WO (1) WO2015162570A1 (cg-RX-API-DMAC10.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20131467A1 (it) 2013-09-06 2015-03-07 Sofar Spa Uso di una composizione comprendente microrganismi per aumentare la produzione intestinale di acido butirrico, di acido folico o di niacina e/o per diminuire la produzione intestinale di acido succinico
MA39710A (fr) 2014-04-23 2015-10-29 Sofar Spa Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
IT201600083376A1 (it) 2016-08-08 2018-02-08 Sofar Spa Uso di probiotici per aumentare l’assorbimento proteico
ITUA20164188A1 (it) 2016-06-08 2017-12-08 Sofar Spa Nuovo uso medico di probiotici
IT201600122724A1 (it) 2016-12-02 2018-06-02 Sofar Spa Exopolysaccharides and uses thereof
IT201600127498A1 (it) 2016-12-16 2018-06-16 Sofar Spa Probiotici per uso nella diverticolosi e malattia diverticolare
IT201600131819A1 (it) * 2016-12-28 2018-06-28 Metis Healthcare S R L Preparazione per spray orale
IT201700101704A1 (it) * 2017-09-12 2019-03-12 Sofar Spa Nuovo uso per trattamento delle infezioni da clostridium difficile
ES3049515T3 (en) * 2017-12-06 2025-12-17 Lac2Biome S R L Composition based on probiotics and uses thereof
CN111973636A (zh) * 2019-05-21 2020-11-24 王飞 一种肛肠凝胶及其制备方法
DK3979982T3 (da) * 2019-06-05 2023-07-03 Lac2Biome S R L Sammensætninger, der omfatter en bakteriestamme lactobacillus paracasei og hyaluronsyre, og anvendelse deraf til hudbehandling
IT201900008409A1 (it) * 2019-06-07 2020-12-07 Vivatis Pharma Gmbh Individuazione e selezione di un materiale di partenza vegetale di condroitina solfato e acido ialuronico vegetali, e trasformazione di tale materiale di partenza vegetale per l’ottenimento di ingredienti per utilizzo in alimenti, integratori, dispositivi medici o farmaci
US11751597B2 (en) 2019-11-05 2023-09-12 Alfasigma S.P.A. Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systems
CN115551524A (zh) * 2020-03-31 2022-12-30 赛瓦图斯有限公司 用于炎性肠病的组合疗法
JP7718672B2 (ja) * 2020-12-25 2025-08-05 日清食品株式会社 腸溶コーティング錠
KR102752058B1 (ko) 2023-08-25 2025-01-13 전남대학교 산학협력단 락토바실러스 루터리 nchbl-005 균주, 사균체 또는 이의 혼합물을 유효 성분으로 포함하는 염증성 질환 예방, 치료 또는 개선용 조성물
IT202300027471A1 (it) * 2023-12-20 2025-06-20 Beingpharma S R L Composizioni cosmetiche e collutori che le contengono per il benessere del cavo orale e dei denti
IT202300027477A1 (it) * 2023-12-20 2025-06-20 Beingpharma S R L Composizioni e collutori che le contengono per il trattamento di disturbi e patologie del cavo orale

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0517363A (ja) * 1991-07-11 1993-01-26 Yakult Honsha Co Ltd 抗炎症剤及びそれを含有する化粧料
US5531989A (en) 1994-10-28 1996-07-02 Metagenics, Inc. Immunoglobulin and fiber-containing composition for human gastrointestinal health
CN1066926C (zh) 1996-04-08 2001-06-13 钟春燕 将椰子水发酵制作的食用纤维及其生产方法
US6461607B1 (en) 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
CZ9900769A3 (cs) 1999-03-04 2000-10-11 Petr Ing. Drsc. Hušek Použití špičky s filtrem k vytvoření sloupce sorbentu s definovaným objemem v prostoru pod filtrem
US20020090416A1 (en) 1999-03-09 2002-07-11 Philip Connolly Method of enhancing absorption and utilization of protein
IT1307850B1 (it) 1999-03-15 2001-11-19 Italmed Di Galli Giovanna E Pa Composizione farmaceutica a base di fermenti lattici e carboidratinon assorbibili contenente un sale di calcio ed un sale di alluminio
EP1145643A1 (en) 2000-04-10 2001-10-17 Phillip Connolly Improved milk protein concentrate
US20040170617A1 (en) 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
RU2182008C1 (ru) * 2000-10-20 2002-05-10 Самойленко Игорь Иннокентьевич Вводимая перорально, ректально или интравагинально композиция, содержащая живые бактерии
US20030092163A1 (en) 2001-07-26 2003-05-15 Collins John Kevin Probiotic bifidobacterium strains
FI20020078A7 (fi) 2002-01-15 2003-07-16 Danisco Immuunijärjestelmän stimulointi polydextroosilla
US6881419B2 (en) 2002-04-09 2005-04-19 William E. Lovett Vitamin formulation for enhancing bone strength
EP1539192A1 (en) * 2002-04-24 2005-06-15 Medicarb AB Composition and kit for the treatment of inflammatory bowel diseases
DK1530642T3 (da) 2002-08-06 2010-03-08 Danisco Brug af lactobacillus til fremstilling af exopolysaccharider i fødevarer og farmaceutiske sammensætninger
AU2002951270A0 (en) 2002-09-06 2002-09-19 Vri Biomedical Ltd Probiotic Bacterium and Methods of Use
WO2005001109A2 (en) 2003-05-06 2005-01-06 Government Of The United States Of America As Represented By The Sercretary Of The Department Of Health And Human Services National Institutes Of Health Methods and compositions to detect microbes in fecal samples
US20100112088A1 (en) 2003-08-29 2010-05-06 Jay Pravda Materials and methods for treatment of disorders associated with oxidative stress
WO2005083122A2 (en) 2004-02-27 2005-09-09 Stichting Laboratorium Voor Infectieziekten Method for detecting a microorganism in a fecal specimen
EP2514427A1 (en) * 2004-03-04 2012-10-24 E-L Management Corp. Skin treatment method with lactobacillus extract
EP1815016B1 (en) 2004-11-01 2012-06-27 George Mason University Compositions and methods for diagnosing colon disorders
CN101175416A (zh) 2005-04-06 2008-05-07 诺瓦提斯公司 从营养方面改善葡萄糖控制和胰岛素作用的方法和组合物
FI20051319L (fi) 2005-12-22 2007-06-23 Cyflo Oy Menetelmä eläimen ja/tai ihmisen ravitsemuksen ja hyvinvoinnin ja eläinten tuottavuuden seuraamiseksi ja kehittämiseksi
CN1840206A (zh) 2006-01-19 2006-10-04 上海交通大学 人源菌群仔猪模型的构建及仔猪肠道中菌群分子检测方法
ES2426038T3 (es) 2006-02-21 2013-10-18 National University Corporation University Of Toyama Procedimiento rápido para identificar el microorganismo causante de una enfermedad infecciosa
WO2007099830A1 (ja) * 2006-02-24 2007-09-07 Q.P. Corporation 新規な低分子ヒアルロン酸および／またはその塩、ならびにこれを用いた化粧料、医薬組成物および食品組成物
US20100166721A1 (en) 2006-06-09 2010-07-01 Fabiola Masri Probotic compositions and uses thereof
US20080069861A1 (en) 2006-09-19 2008-03-20 National Starch And Chemical Investment Holding Corporation Probiotic/Non-Probiotic Combinations
US20080081035A1 (en) 2006-10-03 2008-04-03 National Enzyme Company Therapeutic protease compositions
JP5285617B2 (ja) 2006-12-18 2013-09-11 アドバンスド バイオニュートリション コーポレーション 生きたプロバイオティクスを含む乾燥食物製品
EP1972208A1 (en) 2007-03-16 2008-09-24 Kirin Holdings Kabushiki Kaisha Composition for improving intestinal microflora
RU2009133376A (ru) 2007-03-27 2011-05-10 Дзе Проктер Энд Гэмбл Компани (US) Способы и наборы для введения пробиотиков
US8821928B2 (en) 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
EP2173196B1 (en) 2007-07-06 2011-02-16 N.V. Nutricia Use of probiotics and fibers for diarrhoea
US8193155B2 (en) * 2009-02-09 2012-06-05 Elc Management, Llc Method and compositions for treating skin
US20090098088A1 (en) 2007-10-10 2009-04-16 The Procter & Gamble Company Methods And Kits For The Treatment Of Diverticular Conditions
CN101240315A (zh) 2008-02-21 2008-08-13 上海交通大学 检测药物防癌效果的非损伤性分子方法
CA2721981A1 (en) 2008-05-01 2009-11-05 The Procter & Gamble Company Methods and kits for the treatment of inflammatory bowel disorder conditions
WO2010008272A1 (en) * 2008-07-15 2010-01-21 N.V. Nutricia Treatment of gut motility disorders
JP2010161944A (ja) 2009-01-13 2010-07-29 Syngen Biotech Co Ltd 新型カゼイ菌の亜種（ｓｇ９６）及びこれを含有する菌抑制組成物及びその用途
ES2778836T3 (es) 2009-03-05 2020-08-12 Probiotical Spa Cepas de bacterias que tienen una alta actividad antiinflamatoria
WO2010103132A1 (es) 2009-03-10 2010-09-16 Hero España, S.A. Aislamiento, identificación y caracterización de cepas con actividad probiótica a partir de heces de lactantes alimentados exclusivamente con leche materna
ES2660008T3 (es) 2009-09-23 2018-03-20 Thomas Julius Borody Terapia para infecciones entéricas crónicas
DK2498626T3 (en) 2009-11-12 2015-07-13 Nestec Sa FOOD COMPOSITION TO PROMOTE GAS MICROFLORAL BALANCE AND HEALTH
RU2580040C2 (ru) 2009-12-22 2016-04-10 Проби Аб Неферментированные композиции, включающие фракцию на основе злаков и пробиотик, и их применение
US8575130B2 (en) * 2010-01-04 2013-11-05 Holy Stone Healthcare Co., Ltd. Mixture of hyaluronic acid for treating and preventing inflammatory bowel disease
ITUD20100112A1 (it) * 2010-06-09 2011-12-10 Farma Derma S R L Preparazione per uso vaginale e rettale e relativo procedimento di produzione
US11235008B2 (en) 2011-03-31 2022-02-01 Ganeden Biotech, Inc. Probiotic sports nutrition compositions
WO2012154738A1 (en) * 2011-05-09 2012-11-15 The Cleveland Clinic Foundation Composition and method to improve intestinal health
GB201219873D0 (en) 2012-11-05 2012-12-19 Multigerm Uk Entpr Ltd Diverticulitis treatment
CN102919922A (zh) 2012-11-08 2013-02-13 黑龙江省轻工科学研究院 一种复合益生菌发酵蓝莓果汁粉的制备方法
KR20150134356A (ko) 2013-03-05 2015-12-01 리엑스유니버시테이트 그로닝겐 염증을 억제하기 위한 페칼리 박테리움 프라우스니치이 htf-f (dsm 26943)의 용도
JP6643984B2 (ja) 2013-07-02 2020-02-12 オーストリアノヴァ シンガポール プライベート リミテッド カプセル化細胞を凍結乾燥する方法、凍結乾燥されたカプセル化細胞、凍結乾燥されたカプセル化細胞を含む組成物、ならびに、そのような細胞および組成物の使用
ITMI20131473A1 (it) 2013-09-06 2015-03-07 Sofar Spa Metodo per valutare gli effetti di una composizione comprendente microrganismi sul microbiota intestinale
ITMI20131467A1 (it) 2013-09-06 2015-03-07 Sofar Spa Uso di una composizione comprendente microrganismi per aumentare la produzione intestinale di acido butirrico, di acido folico o di niacina e/o per diminuire la produzione intestinale di acido succinico
MA39710A (fr) * 2014-04-23 2015-10-29 Sofar Spa Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
WO2015172191A1 (en) 2014-05-12 2015-11-19 Medlab Ip Pty Ltd Probiotic compositions and uses thereof for treatment of obesity-related disorders
EP2990045B1 (en) 2014-08-26 2016-11-16 Chr. Hansen A/S Bifidobacterium animalis subsp. lactis for use in decreasing abdominal pain in a postmenopausal woman
IT201600083376A1 (it) 2016-08-08 2018-02-08 Sofar Spa Uso di probiotici per aumentare l’assorbimento proteico
WO2017195182A1 (en) 2016-05-13 2017-11-16 Sofar S.P.A. Use of probiotics for improving protein absorption
ITUA20164188A1 (it) 2016-06-08 2017-12-08 Sofar Spa Nuovo uso medico di probiotici
IT201600122724A1 (it) 2016-12-02 2018-06-02 Sofar Spa Exopolysaccharides and uses thereof
US11207358B2 (en) 2016-12-16 2021-12-28 Compagnie Gervais Danone Probiotic composition comprising Lactobacillus rhamnosus and Lactobacillus paracasei and methods thereof
IT201600127498A1 (it) 2016-12-16 2018-06-16 Sofar Spa Probiotici per uso nella diverticolosi e malattia diverticolare
WO2019019961A1 (zh) 2017-07-26 2019-01-31 海思科医药集团股份有限公司 防治消化道和/或皮肤反应的菌群及其应用
IT201700101704A1 (it) 2017-09-12 2019-03-12 Sofar Spa Nuovo uso per trattamento delle infezioni da clostridium difficile
ES3049515T3 (en) 2017-12-06 2025-12-17 Lac2Biome S R L Composition based on probiotics and uses thereof
CN108743851A (zh) 2018-08-09 2018-11-06 深圳市博奥生物科技有限公司 一种复合益生菌粉的制备方法及复合益生菌粉
IT201900016811A1 (it) 2019-09-20 2021-03-20 Sofar Spa Ceppi batterici, loro composizioni e loro uso per il trattamento di disturbi gastrointestinali
IT201900016805A1 (it) 2019-09-20 2021-03-20 Sofar Spa Ceppi batterici, loro composizioni e loro uso per il trattamento di disturbi gastrointestinali
IT201900016865A1 (it) 2019-09-20 2021-03-20 Sofar Spa Composizioni a base di ceppi batterici e loro uso come antinfiammatori
IT201900016850A1 (it) 2019-09-20 2021-03-20 Sofar Spa Composizioni a base di ceppi batterici e estratti di bacche e loro uso come antinfiammatori
US11751597B2 (en) 2019-11-05 2023-09-12 Alfasigma S.P.A. Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systems
IT201900020422A1 (it) 2019-11-05 2021-05-05 Sofar Spa Composizioni comprendenti ceppi di batteri per uso per aumentare la biodisponibilità degli amminoacidi derivanti da proteine

Also Published As

Publication number Publication date
CA2944118A1 (en) 2015-10-29
JP2017513906A (ja) 2017-06-01
US20170035816A1 (en) 2017-02-09
MA39710A (fr) 2015-10-29
US11464814B2 (en) 2022-10-11
US20230052820A1 (en) 2023-02-16
EP3134072A1 (en) 2017-03-01
WO2015162570A1 (en) 2015-10-29

Similar Documents

Publication Publication Date Title
US20230052820A1 (en) Topical composition for use in the treatment of inflammatory bowel disease
JP7680376B2 (ja) 細菌株ラクトバチルス・パラカゼイおよびヒアルロン酸を含む組成物および皮膚の治療のためのその使用
US11839645B2 (en) Therapeutic use of engineered postbiotics comprising bacteriocins and/or endolysins
KR101279852B1 (ko) 골다공증 예방 또는 치료용 조성물
US10155015B2 (en) Probiotic compositions for use in the treatment of bowel diseases
BRPI0314060B1 (pt) composição compreendendo variante ou componente de variante de lactobacillus fermentum e usos da variante ou componente de variante de lactobacillus fermentum e da composição
US20100092440A1 (en) composition for the administration of biologically active principles in gynaecologic and rectal field and uses thereof
CN1211189A (zh) 含衍自杜鹃花科植物的物质和乳酸菌生长因子的,用于泌尿生殖系统和肠道疾病的组合物
JP7126004B2 (ja) 組成物及びその使用
ES2875765T3 (es) Nueva cepa bacteriana probiótica de Lactobacillus Plantarum y composiciones y usos de la misma en el tratamiento de inflamación
JP2012040015A (ja) 食養生製品、食品添加物または医薬用アルカリ性スフィンゴミエリナーゼ含有組成物
O'Sullivan et al. Protecting the outside: biological tools to manipulate the skin microbiota
CA3123125A1 (en) Strains, composition and method of use
CN114040770B (zh) 用于治疗、缓和或预防痤疮的组合物
JP6665099B2 (ja) 乳酸菌含有組成物
Daniluk et al. Probiotic-induced apoptosis and its potential relevance to mucosal inflammation of gastrointestinal tract
CN101357142B (zh) 酪酸梭菌在制备防治心脑血管疾病药物组合物中的应用
JP7118594B2 (ja) 止瀉剤組成物
JP6061530B2 (ja) Ｎａｓｈ予防治療剤
JP7654014B2 (ja) 細菌株を含む組成物、ならびに眼の疾患および病変の処置のための同組成物の使用
Dastoor et al. Probiotics for life–Part I general health perspectives
JPH045236A (ja) 抗潰瘍剤およびその製造法
JP2021531015A (ja) アデノシンレベルを増加させることができる細菌株を使用する治療法
JP2024157617A (ja) 乾癬の予防、治療又は改善剤
RU2021131955A (ru) Пробиотические композиции и их применение

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180418

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251001

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260112

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260112

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260603